Why the study?
It was unknown whether chlorogenic acid could improve diabetic cardiomyopathy by inhibiting hyperglycemia-induced cardiac fibrosis.
Does chlorogenic acid alleviate hyperglycemia-induced cardiac fibrosis in a Type I diabetic mouse model?
Population
Streptozotocin-induced type I diabetic mice and cardiac fibroblasts
Comparison
Chlorogenic acid treatment vs untreated controls
Design
In vivo animal and in vitro preclinical study
Follow-up
12 weeks
Key result
Chlorogenic acid significantly attenuated hyperglycemia-induced cardiac fibrosis and improved cardiac functions in Type I diabetic mice through activation of the NO/cGMP/PKG pathway.
Authors
Loading...
CGA may benefit diabetic cardiomyopathy; hypothesis-generating in mice, requiring human trials before any practice change.
Does chlorogenic acid alleviate hyperglycemia-induced cardiac fibrosis in a Type I diabetic mouse model?
Chlorogenic acid demonstrates anti-fibrotic effects in diabetic cardiomyopathy through the NO/cGMP/PKG pathway, independent of its glucose-lowering properties.
Qin et al. (2020) studied Hyperglycemia-induced cardiac fibrosis in Type I diabetes. Chlorogenic acid (CGA) was evaluated on Cardiac functions and fibrosis. Chlorogenic acid significantly attenuated hyperglycemia-induced cardiac fibrosis and improved cardiac functions in Type I diabetic mice through activation of the NO/cGMP/PKG pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: